BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:EicOsis Human Health\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies EicOsis Human Health\, Inc.'s dru
 gs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07142044-8731@assetmemo.bio
DTSTAMP:20261121T010844Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:EC5026: Phase 1/2 readout est. (NCT07142044)
DESCRIPTION:EC5026\, phase 1/2\, Parkinson's Disease.\nStudy: Safety\, Tole
 rability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP S
 tudy)\nEstimated primary completion: December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/ec5026#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07142044
URL:https://assetmemo.bio/drug/ec5026#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
